On the stock market since 2016, it operates in the world of health and science. It has 49 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 100% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
An investor who bought at the very peak is down 94% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $38.8M in the vault; even if every debt were paid off, $25.3M would remain.
A loss of $228K against $0 in annual sales.
The stock sits at $0.78. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 2.1 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, ERYP sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: ERYP is a high-risk stock — not yet profitable, and its future rides on its product catching on.